Nikolaos A. Chinas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nikolaos A. Chinas has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Harry Alexopoulos
Department of Cell Biology and Biophysics Faculty of Biology National and Kapodistrian University of Athens Athens Greece
2 shared publications - Stella Kaliampou
Department of Dermatology-Venereology, 251 Hellenic Air Force General Hospital, Athens, Greece
1 shared publication - Vasiliki Nikolaou
Department of Dermatology‐Venereology, Faculty of Medicine National and Kapodistrian University of Athens, “A. Sygros” Hospital for Skin and Venereal Diseases Athens Greece
1 shared publication
Latest Publications
- Open Access
- 28 July 2026
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 46 (1)
Glutamate, Immune Cells and Alzheimer’s Disease: An Attempt to Link the Triad
Glutamate (Glu), although the main excitatory neurotransmitter (NT) of the central nervous system (CNS), evidence recognizes its role in influencing immune cell function and activation, including cytokine production, cell proliferation, migration, and survival. Importantly, dysregulation of Glu homeostasis has been implicated in the pathogenesis of Alzheimer’s disease (AD), a neurodegenerative disorder characterized by progressive cognitive decline, neuronal loss and neuroinflammation. This review synthesizes current evidence on the biochemistry of the glutamatergic synapse, as well as the expression and signaling of Glu receptors (GluRs) in human immune cells. Furthermore, it examines two major hypotheses of AD pathogenesis —the glutamatergic and the neuroimmune hypothesis— and proposes a unified glutamatergic–neuroimmune framework. In this model, disrupted glutamatergic signaling at the neuron–glia–immune interface may represent a central contributor to AD pathology. Understanding the glutamatergic–neuroimmune axis may provide novel insights into therapeutic strategies targeting neuroimmune modulation in AD.
- 28 July 2026
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 46 (1)
Open AccessGlutamate, Immune Cells and Alzheimer’s Disease: An Attempt to Link the Triad
Glutamate (Glu), although the main excitatory neurotransmitter (NT) of the central nervous system (CNS), evidence recognizes its role in influencing immune cell function and activation, including cytokine production, cell proliferation, migration, and survival. Importantly, dysregulation of Glu homeostasis has been implicated in the pathogenesis of Alzheimer’s disease (AD), a neurodegenerative disorder characterized by progressive cognitive decline, neuronal loss and neuroinflammation. This review synthesizes current evidence on the biochemistry of the glutamatergic synapse, as well as the expression and signaling of Glu receptors (GluRs) in human immune cells. Furthermore, it examines two major hypotheses of AD pathogenesis —the glutamatergic and the neuroimmune hypothesis— and proposes a unified glutamatergic–neuroimmune framework. In this model, disrupted glutamatergic signaling at the neuron–glia–immune interface may represent a central contributor to AD pathology. Understanding the glutamatergic–neuroimmune axis may provide novel insights into therapeutic strategies targeting neuroimmune modulation in AD.
- Open Access
- 18 July 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1604174
CAR T-cells meet autoimmune neurological diseases: a new dawn for therapy
Autoimmunity and autoimmune diseases arise when the immune system erroneously targets self-antigens leading to tissue damage. Consequently, immunomodulatory and mainly immunosuppressive drugs comprise the conventional treatment in conditions such as systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis. However, many of these agents often fall short of providing a cure and have a limit on symptom management. This underscores the urgent need for even more advanced therapies for patients to constrain progressive disability. Therefore, currently, researchers explore the potential of chimeric antigen receptor (CAR) T-cell therapy for autoimmune diseases considering its success in cancer treatment and specifically in hematological malignancies. This review will examine recent advancements in CAR T-cell therapy for autoimmune disorders, highlighting how CAR T cells can be engineered to precisely target and eliminate autoreactive immune cells that drive these debilitating diseases, particularly those affecting the nervous system such as Multiple sclerosis, Myasthenia gravis, Neuromyelitis optica, Stiff-person syndrome, Autoimmune encephalitis, MOG-antibody disease and Chronic inflammatory demyelinating polyneuropathy. Also, through an analysis of preclinical and clinical data, we will assess the efficacy, safety, potential side effects and limitations of these innovative therapies. Lastly, we will underline the transformative potential of CAR T-cells in Autoimmune Neurology, offering a promising new hope for treatment where conventional therapies have failed.
- 18 July 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1604174
Open AccessCAR T-cells meet autoimmune neurological diseases: a new dawn for therapy
Autoimmunity and autoimmune diseases arise when the immune system erroneously targets self-antigens leading to tissue damage. Consequently, immunomodulatory and mainly immunosuppressive drugs comprise the conventional treatment in conditions such as systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis. However, many of these agents often fall short of providing a cure and have a limit on symptom management. This underscores the urgent need for even more advanced therapies for patients to constrain progressive disability. Therefore, currently, researchers explore the potential of chimeric antigen receptor (CAR) T-cell therapy for autoimmune diseases considering its success in cancer treatment and specifically in hematological malignancies. This review will examine recent advancements in CAR T-cell therapy for autoimmune disorders, highlighting how CAR T cells can be engineered to precisely target and eliminate autoreactive immune cells that drive these debilitating diseases, particularly those affecting the nervous system such as Multiple sclerosis, Myasthenia gravis, Neuromyelitis optica, Stiff-person syndrome, Autoimmune encephalitis, MOG-antibody disease and Chronic inflammatory demyelinating polyneuropathy. Also, through an analysis of preclinical and clinical data, we will assess the efficacy, safety, potential side effects and limitations of these innovative therapies. Lastly, we will underline the transformative potential of CAR T-cells in Autoimmune Neurology, offering a promising new hope for treatment where conventional therapies have failed.
- Open Access
- 8 March 2025
- Published by Springer Nature in Current Oncology Reports
- Vol. 27 (4) , 415-430
Unveiling the Role of the Cellular Tumor Microenvironment and the Therapeutic Targets it Provides in Cutaneous T-Cell Lymphoma
Purpose of Review: Cutaneous T-Cell Lymphoma (CTCL) poses challenges both in diagnosis and prognosis. The purpose of this review is to address the role of profiling immune and non-immune cells in the tumor microenvironment (TME) as it provides information for better diagnosis, prognosis, biomarker discovery, and personalized treatment strategies. Recent Findings: Recent evidence suggests that the progression of CTCL is closely linked to the Tumor Microenvironment (TME) which comprises various cell types including immune cells, stromal cells, blood vessels, and the extracellular matrix. Cell profiling within the TME demonstrates the perplexity of intracellular communication of the different cell fates and their mediators as the disease progresses. Summary: CTCL as a rare form of non-Hodgkin lymphoma often misdiagnosed due to its similarity to other skin conditions. It encompasses diseases like Mycosis fungoides (MF) and Sézary Syndrome (SS), with the latter being more severe. Advances in studying the TME have shown its pivotal role in CTCL progression, highlighting the need for comprehensive cell profiling to enhance diagnosis, prognosis, and treatment personalization.
- 8 March 2025
- Published by Springer Nature in Current Oncology Reports
- Vol. 27 (4) , 415-430
Open AccessUnveiling the Role of the Cellular Tumor Microenvironment and the Therapeutic Targets it Provides in Cutaneous T-Cell Lymphoma
Purpose of Review: Cutaneous T-Cell Lymphoma (CTCL) poses challenges both in diagnosis and prognosis. The purpose of this review is to address the role of profiling immune and non-immune cells in the tumor microenvironment (TME) as it provides information for better diagnosis, prognosis, biomarker discovery, and personalized treatment strategies. Recent Findings: Recent evidence suggests that the progression of CTCL is closely linked to the Tumor Microenvironment (TME) which comprises various cell types including immune cells, stromal cells, blood vessels, and the extracellular matrix. Cell profiling within the TME demonstrates the perplexity of intracellular communication of the different cell fates and their mediators as the disease progresses. Summary: CTCL as a rare form of non-Hodgkin lymphoma often misdiagnosed due to its similarity to other skin conditions. It encompasses diseases like Mycosis fungoides (MF) and Sézary Syndrome (SS), with the latter being more severe. Advances in studying the TME have shown its pivotal role in CTCL progression, highlighting the need for comprehensive cell profiling to enhance diagnosis, prognosis, and treatment personalization.